Unknown

Dataset Information

0

Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy.


ABSTRACT: Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy.Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy.CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses.Collectively, results validate dendritic cells stimulatory response to CpG-NP-Tag NPs (ex vivo) and CpG-NP-Tag NPs' tumor inhibitory potential (in vivo) for therapeutic applications, respectively.

SUBMITTER: Kokate RA 

PROVIDER: S-EPMC5563943 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7227821 | BioStudies
2015-01-01 | S-EPMC4839968 | BioStudies
1000-01-01 | S-EPMC6136913 | BioStudies
2020-01-01 | S-EPMC7174389 | BioStudies
1000-01-01 | S-EPMC4104924 | BioStudies
2013-01-01 | S-EPMC3524336 | BioStudies
2016-01-01 | S-EPMC5098754 | BioStudies
2019-01-01 | S-EPMC6628902 | BioStudies
2019-01-01 | S-EPMC6796886 | BioStudies
2016-01-01 | S-EPMC5105989 | BioStudies